In a small study, NIH researchers found that positron emission tomography (PET) scans of the heart may identify people who will develop Parkinson’s disease or Lewy body dementia among those at-risk for these diseases.

Cardiovascular-related deaths due to extreme heat are expected to increase between 2036 and 2065 in the U.S., according to an NIH-supported study.

NIH researchers have developed a way to potentially increase the effectiveness of T cell-based immunotherapy treatments, such as CAR T-cell therapy, against solid tumors.

SARS-CoV-2, the virus that causes Covid-19, can directly infect the arteries of the heart and cause the fatty plaque inside arteries to become highly inflamed, increasing the risk of heart attack and stroke, according to an NIH-funded study.

An NIH-funded research team has developed a smartphone app that can track and analyze a person’s ability to move from one place to another, known as locomotion, and other types of movements.

An investigational drug, encaleret, restored calcium levels in people with autosomal dominant hypocalcemia type 1 (ADH1), a rare genetic disorder marked by an imbalance of calcium in the blood and urine. People with ADH1 have abnormally low levels of parathyroid hormone, which regulates blood calcium levels.

Researchers identified uric acid as a potential therapy to enhance recovery from acute ischemic stroke. In the study, researchers from NIH’s Stroke Preclinical Assessment Network (SPAN) rigorously tested the effectiveness of six novel therapies in reducing ischemic brain injury in rodents, including four FDA-approved drugs to treat other conditions.

Using a novel deep brain stimulation (DBS) device capable of recording brain signals, researchers have identified a pattern of brain activity or “biomarker” related to clinical signs of recovery from treatment-resistant depression.

NIH launched a clinical trial to test whether early intensive immune modulation for hospitalized Covid-19 patients with relatively mild illness is beneficial.

Past-year use of marijuana and hallucinogens by adults ages 35 to 50 continued a long-term upward trajectory to reach all-time highs in 2022, according to the Monitoring the Future (MTF) panel study, an annual survey of substance use behaviors and attitudes of adults 19 to 60 years old.